Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 17/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 2/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.41 |
| ▸ | KIT | P10721 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3332383 | 1.00 | IRAK4 (0.48) | IRAK4DYRK1APIM1MAPK10FLT3 | |
| SCHEMBL3332386 | 1.00 | IRAK4 (0.48) | IRAK4DYRK1APIM1MAPK10FLT3 | |
| SCHEMBL3332914 | 0.86 | IRAK4 (0.62) | IRAK4DYRK1APIM1FLT3MAPK8 | |
| SCHEMBL1978158 | 0.83 | PIM1 (0.66) | PIM1 | |
| SCHEMBL1978162 | 0.83 | PIM1 (0.66) | PIM1 | |
| SCHEMBL3330634 | 0.82 | KDR (0.63) | FLT3KITKDR | |
| SCHEMBL3330645 | 0.82 | KDR (0.63) | FLT3KITKDR | |
| SCHEMBL13300958 | 0.80 | PIM1 (0.55) | IRAK4DYRK1APIM1MAPK10FLT3 | |
| SCHEMBL3335421 | 0.80 | PIM1 (0.69) | IRAK4DYRK1APIM1MAPK10FLT3 | |
| SCHEMBL27778876 | 0.79 | PIM1 (0.52) | IRAK4DYRK1APIM1MAPK10FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144751-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100144751-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100144751-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-06-10 | — | — | US | disclosed |
| CN-101679422-A | Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA INC | 2010-03-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144751-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | PIM1, PIM3, PIM2 | IRAK4 29/4885DYRK1A 416/4885PIM1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.